Corestemchemon Completes Application for Manufacturing Site Change Approval for 'Neuronata-Alzu'…'Full-Scale Sales Expected'
Predicted impact: Medium
Manufacturing site change filing for Neuronata-Alzu; sales hopes, revenue base small at about ₩18B
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.